PowerPoint プレゼンテーション

NLR dNLR

IPMN LGD

IPMN HGD

IPMN INV

IPMN with PDAC 0.5

1 2 4 8 16

Neutrophil-to-lymphocyte ratio

1.74 1.84 2.17 2.30

P = P = P = 0.1648

0.0023 0.0105

Median

IPMN LGD

IPMN HGD

IPMN INV

IPMN with PDAC 0

100 200 300300 600 900 1200

Platelet-to-lymphocyte ratio

P = P = P = 0.8093

0.0209

130.4 137.0 146.7 126.7 0.8647

Median

PLR CAR

IPMN LGD

IPMN HGD

IPMN INV

IPMN with PDAC 0.0010.010.01

0.10.1 1 10

CRP-to-albumin ratio

P = P = P = 0.1635

0.0059

0.0250 0.0256 0.0263 0.0294 0.0013

Median

IPMN LGD

IPMN HGD

IPMN INV

IPMN with PDAC 0

1 2 3 4 5

derived neutrophil-to-lymphocyte ratio

1.27 1.33 1.56 1.63 P =

P = P = 0.3344

0.0044 0.0418

Median

NLR dNLR

PLR CAR

IPMN LGD an HGD

IPMN INV 0.5

1 2 4 8 16

Neutrophil-to-lymphocyte ratio

1.78

(1.42¾2.44) 2.17

(1.62¾3.30) Median

(IQR)

P = 0.0071

IPMN LGD an HGD

IPMN INV 0

1 2 3 4 5

derived Neutrophil-to-lymphocyte ratio

1.27

(1.04¾1.79) 1.56 (1.21¾2.22) Median

(IQR)

P = 0.0078

IPMN LGD an HGD

IPMN INV 0

100 200 300300 600 900 1200

Platelet-to-lymphocyte ratio

134.1

(97.0¾181.5) 146.7 (122.6¾203.9) Median

(IQR)

P = 0.0170

IPMN LGD an HGD

IPMN INV 0.01

0.1 1 10

CRP-to-albumin ratio

0.0250

(0.0238¾0.0294) 0.0263 (0.0244¾0.0485) Median

(IQR)

P = 0.0174

Supplementary Figure S3. Receiver operating characteristic curve

analysis for the diagnostic accuracy of NLR (A) and CAR (B) in predicting the presence of high-grade dysplasia/invasive carcinoma among 205 IPMN cases.

AUC, area under the curve; NLR, neutrophil-to-lymphocyte ratio; CAR C- reactive protein-to-albumin ratio

0 20 40 60 80 100 0

20 40 60 80 100

100% - Specificity (%)

S en si ti vi ty ( % )

AUC: 0.5998

CAR

0 20 40 60 80 100 0

20 40 60 80 100

100% - Specificity (%)

S en si ti vi ty ( % )

0.6052 AUC:

NLR